EUDA Health Holdings Limited announced on January 7 2026 that it had entered into an amendment to its warrant agreement with Streeterville Capital, LLC. The amendment, executed on December 16 2025, reduces the exercise price of the warrants from $6.00 to $4.00 per share and lowers the forced‑exercise trigger price from $7.50 to $6.00. The warrant transaction was originally signed on November 26 2025, the warrants were issued on December 4 2025, and the purchase price was $100,000 for a maximum of 2,000,000 ordinary shares. The cash exercise period is 90 days from issuance, after which a cashless exercise ratio of one ordinary share for every ten warrants applies, with an additional two‑week grace period.
The reduction in exercise price and trigger price makes the warrants more attractive to Streeterville Capital, increasing the likelihood that the warrants will be exercised in the near term. If exercised, the company would receive up to $8 million in new capital, but the issuance of up to 2 million new shares would dilute existing shareholders. The amendment also shortens the cash exercise window, allowing the company to convert the warrants into cash more quickly and thereby improve its liquidity profile.
EUDA Health’s financial performance has been under pressure, with negative revenue growth over the past three years and operational inefficiencies reflected in its margins. The company’s focus on the longevity sector and its expansion into digital health and stem‑cell therapy platforms have required significant capital outlays. The warrant amendment is therefore a strategic move to shore up liquidity amid a challenging revenue environment and to support ongoing investment in high‑growth initiatives.
The amendment signals management’s intent to secure additional capital while balancing the need to protect shareholder value through a lower exercise price. It also reflects the company’s broader strategy of pursuing longevity‑focused healthcare services and property management in Singapore, Malaysia, and China. By making the warrants more attractive, EUDA Health aims to attract investment that can fund its expansion plans without immediately diluting the equity base to a greater extent than necessary.
The amendment is a material event that will influence the company’s capital structure and liquidity position, warranting coverage for investors monitoring EUDA Health’s financial health and strategic direction.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.